Pyrotinib
EBV-Positive DLBCL, Nos
Ruijin HospitalSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the EBV-Positive DLBCL, Nos cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Patrick C. Johnson, MD | Phase 2 | B |
DEXAMETHASONE University of Washington | Phase 2 | B |
Acalabrutinib Patrick C. Johnson, MD | Phase 2 | CCC |
Jcar017 (Lisocabtagene Maraleucel) Patrick C. Johnson, MD | Phase 2 | CCC |
Fludarabine Jennifer Crombie, MD | Phase 2 | CCC |
View all 14 →
Same molecule, other indications
Pyrotinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →